An attempt by Merck & Co. to shorten hepatitis C treatment to just four weeks by adding Gilead Sciences' huge-selling Sovaldi to its own oral two-drug combination came nowhere near the desired efficacy due to a high rate of relapses, according to interim data from a midstage study.
Merck four-week hep C regimen with Gilead's Sovaldi comes up short
Letter
to the
Editor
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.
Sponsored Content